Showing results (251-260 of 270) with videos related to
Sort By:
Pageof 27
The New England Journal of Medicine|May 30, 2020
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsPaul K Paik, Enriqueta Felip, Remi Veillon, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2020
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLCLingzhi Hong, Marcelo V Negrao, Seyedeh S Dibaj, et al.Nature Medicine|May 29, 2023
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistanceYanshuo Chu, Enyu Dai, Yating Li, et al.Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2026
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational ImpactMichele Carbone, Christopher Amos, Richard L Attanoos, et al.European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.Nature Communications|November 18, 2021
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancerMing Chen, Runzhe Chen, Ying Jin, et al.Journal of the National Cancer Institute|April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCImane Chaib, Niki Karachaliou, Sara Pilotto, et al.Cancer|May 30, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS RegistryFrancesco Passiglia, Antonio Passaro, Eleonora Gariazzo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.Pageof 27